Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Apyx Medical Corp. (“Apyx” or the “Company”) (NASDAQ: APYX) on behalf of Apyx stockholders. Our investigation concerns whether Apyx has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On March 14, 2022, Apyx disclosed that the U.S. Food and Drug Administration (“FDA”) would be posting a Medical Device Safety Communication (“MDSC”) related to the Company’s Advanced Energy Products. The Company further disclosed that “[b]ased on our initial interactions with the FDA, we believe the Agency’s MDSC will pertain to the use of our Advanced Energy products outside of their FDA-cleared indication for general use in cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures.”
On this news, Apyx’s share price fell $4.02, or 40.6%, to close at $5.88 per share on March 14, 2022, thereby injuring investors.
If you purchased or otherwise acquired Apyx shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra Raymond by email at email@example.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.